在百万退伍军人计划中,皮肤冠状动脉干预 (PCI) 后的多态和临床结果
Catherine Chanfreau-Coffinier1, Kevin A Friede2, Mary E Plomondon3
1VA Salt Lake City Heath Care System, Salt Lake City, UT.
在PCI后,CYP2C19功能丧失等位基因增加了急性冠状动脉综合征患者的MACE风险. 然而,CYP2C19基因型对用克洛皮多格雷尔治疗的稳定缺血性心脏病患者的MACE风险没有影响.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 已知CYP2C19功能丧失 (LOF) 基因基因在急性冠状动脉综合征 (ACS) 患者中降低了皮格雷尔在皮肤穿刺冠状动脉干预 (PCI) 后的抗血小板疗效.
- 在接受PCI的稳定性缺血性心脏病 (SIHD) 患者中,CYP2C19基因型的临床意义仍然不太清楚.
结论:
- 在PCI后用克洛皮多格勒治疗ACS的CYP2C19 LOF载体面临MACE的数量增加风险.
- CYP2C19基因型似乎与接受PCI并接受克洛皮多格雷尔治疗的SIHD患者的MACE风险无关.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy II: Dilated Cardiomyopathy
